DISMUTEC TRIAL FAILS TO REACH STATISTICAL SIGNIFICANCE.PISCATAWAY, N.J.--(BUSINESS WIRE)--October 19, 1995--Enzon, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ENZN) announced today that is has been advised by Sanofi Winthrop, Inc. that the Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of DISMUTEC (pegorgotein) in patients with severe closed head injury has been evaluated and fails to show a statistically significant difference between the treatment group and the control group. DISMUTEC, the enzyme superoxide dismutase superoxide dismutase n. An enzyme that catalyzes the decomposition of a superoxide into hydrogen peroxide and oxygen. superoxide dismutase modified with Enzon's proprietary PEG- technology, is designed to decrease tissue injury caused by ischemia or trauma in severe closed head injury patients. Through modification with Enzon's PEG-technology, DISMUTEC exhibited longer circulating half-life and reduced immunogenicity immunogenicity /im·mu·no·ge·nic·i·ty/ (-je-nis´it-e) the property enabling a substance to provoke an immune response, or the degree to which a substance possesses this property. ; however, the drug showed insufficient therapeutic effect for this indication. "Although the results of the clinical trial were disappointing for this product, there is no immediate impact on Enzon from an earnings or cash flow perspective and these results in no way reflect adversely on the Company's other products or PEG- technology," stated Peter G. Tombros, Enzon's president and chief executive officer. Enzon has two FDA-approved products based on the PEG-technology: l V ADAGEN for the treatment of ADA-deficient Severe Combined Immunodeficiency Disease Noun 1. severe combined immunodeficiency disease - a congenital disease affecting T cells that can result from a mutation in any one of several different genes; children with it are susceptible to infectious disease; if untreated it is lethal within the first year or and ONCASPAR for the treatment of Acute Lymphoblastic Leukemia acute lymphoblastic leukemia n. Abbr. ALL Lymphoblastic leukemia occurring mainly in older adults, characterized by rapid onset and progression of symptoms. Also called acute lymphocytic leukemia. , which is marketed in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. by Rhone-Poulenc Rorer Pharmaceuticals Inc. Enzon is developing advanced therapeutics for life-threatening diseases primarily in the areas of cancer therapy, blood substitutes and genetic diseases and maintains a full product pipeline in various stages of development. The Company has formed strategic alliances with healthcare partners including Rhone-Poulenc Rorer Pharmaceuticals, Eli Lilly, Bristol-Myers Squibb, Baxter Healthcare and others. Enzon is headquartered in Piscataway, NJ. CONTACT: Kenneth Zuerblis Enzon, Inc. (908) 980-4717 or Donna Brasko Enzon, Inc. (908) 980-4577 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion